Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

Sorafenib exerts modest antitumor activity in patients with advanced hepatocellular carcinoma (HCC), and radiological progressive disease (rPD) does not always correspond to so-called clinical progressive disease (cPD). We evaluated 101 patients who initiated sorafenib treatment for HCC and assessed...

Full description

Saved in:
Bibliographic Details
Published in:Diseases
Main Authors: Otsuka, Taiga, Nakashita, Shunya, Yanagita, Kimihiko, Ario, Keisuke, Kawasoe, Hiroaki, Kawazoe, Seiji, Eguchi, Yuichiro, Mizuta, Toshihiko
Format: Artigo
Language:Inglês
Published: MDPI 2015
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5548234/
https://ncbi.nlm.nih.gov/pubmed/28943609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/diseases3020068
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items